Please login to the form below

Not currently logged in
Email:
Password:

Servier defends Perindopil overcharging claim

Servier refutes claims made by the UK's Department of Health the company is overcharging for high blood pressure and heart disease drug Perindopil

Servier is contesting legal action by the UK's Department of Health (DH), which claims the French drug manufacturer charged £220m too much for its high blood pressure and heart disease drug perindopril.

A report in the UK paper, the Daily Mail, alleges that Health Secretary Andrew Lansley has accused Servier of forcing doctors to pay for expensive versions of the pills when generic ones were available.

Lansley also alleges that the company paid millions of pounds to rivals not to make generic versions, after its patent ran out in 2001, according to the report.

Lansley is leading the action at the High Court with ten strategic health authorities and 157 primary care trusts to reclaim money the NHS was overcharged between 2001 and 2007.

A spokeswoman for Servier said: "We are contesting the claim and we are confident that the right outcome will be reached."

Meanwhile a spokeswoman for the DH told PMLiVE that the department could not comment on ongoing proceedings.

Earlier this year Lansley took legal action against Reckitt Benckiser, claiming nearly £90m for overcharging for heartburn drugs.

7th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics